Memorial “Alicia Pueyo” Workshop

March 12, 2018

Welcome Chair: Jaume Mora

Session 1: Cell of Origin, Structure and Microenvironment. 8:30 to 12:30

1. NADA JABADO. McGill University, Montreal, Quebec, Canada.
   Spatiotemporal Homogeneity (20’)

2. VIVIANE TABAR. MSKCC
   H3K27M and what else? (20’)

Break 1: 10:00 to 10:30 AM   Coffee break

3. MICHELLE MONJE. Department of Neurology, Stanford University.
   H3K27M and PDGFR (20’)

4. ESTHER HULLEMAN. VU University Medical Center, Amsterdam.
   EMT programs and DIPG (20’)

5. MARIELLA FILBIN. Dana-Farber Cancer Institute. Boston
   Oligodendrocyte precursor cells (20’)

Break 2: 12:30 to 14:00 PM Lunch
Session 2: Current DIPG management and Clinical Trials. 14:00 to 18:00 PM

Short Abstract Presentation #1:  
**Sonia Paco**, HSJD laboratory  
Immune microenvironment in DIPG and normal Brainstem

1. **ANDRES MORALES.** Pediatric Neuro-Oncology. HSJD Barcelona.  
   Immunotherapy clinical trial with dendritic cell vaccination for newly diagnosed DIPG (20’)

2. **LORENZA GANDOLA.** Istituto Nazionale dei Tumori, Milan.  
   Radiotherapy strategies for the management of DIPG patients. (20’)

3. **DANNIS VAN VUURDEN.** VU University Medical Center, Amsterdam.  
   SIOP-BTG strategies (20’)

Break 3: 15:30 to 16:00 AM Coffee break

4. **MARK KIERAN.** Dana-Farber Cancer Institute, Boston.  
   BATS DIPG study. The USA perspective (20’)

5. **JACQUES GRILL.** Institut de cancérologie Gustave Roussy, Paris.  
   BIOMEDE study. The European perspective. (20’)

6. **MARK M. SOUWEDAINÉ.** Weill Medical College of Cornell University, NY.  
   CED strategies for DIPG control. How close?. (20’)

Short Abstract Presentation #2:  
**Javad Nazarian.** George Washington University, Washington DC  
Liquid biopsies in DIPG
Workshop Dinner

March 13, 2018

Session 3: Let’s start the future: Pre-clinical platforms, novel targets, potential therapies and delivery systems. 8:00 to 13:00 PM

1. CHRIS JONES. The Institute of Cancer Research, Sutton, UK.
   ACVR1 and beyond. (20’)

2. KATHY WARREN. Pediatric Oncology Branch, NCI. USA.
   Beyond the BBB: The Importance of CNS Pharmacokinetics (20’)

3. OREN BECHER. Northwestern University, Chicago.
   The CDK4/6 and PDGF-B story (20’)

Short Abstract Presentation #3
Meritxell Teixidó, Institut de Recerca Biomèdica de Barcelona IRB
Nanocarriers for BBB shuttling

Break 4: 10:00 to 10:30 AM  Coffee break

   Dasatinib, Cabozantinib and others (15’)

5. MICHELLE MONJE. Department of Neurology, Stanford University, Stanford.
   Neuronal activity/ Neuroligin/ BRD and HDAC inhibitors/CDK7 inhibition (15’)

6. ESTHER HULLEMAN. VU University Medical Center, Amsterdam.
   Preclinical platforms to evaluate CED (15’)

7. MARTA ALONSO. CIMA. Universidad de Navarra. Pamplona. Spain
   Oncolytic virotherapy for DIPG Treatment (15’)

3
8. ANGEL M. CARCABOSO. Developmental tumor Laboratory. HSJD

CNS penetrating drugs to inhibit migration and invasión of DIPG. (15’)

Closing session: The families support and impulse. 12:30 to 13:00 PM

GLORIA CARCIA (Alicia’s mother): the DIPG foundations International Alliance. Fund-raising initiatives to support DIPG research.